INCY Overview
Upcoming Projects (INCY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (INCY)
-
A look at the recent approval of Eli Lilly and Incyte's Olumiant (baricitinib) and potential use in alopecia areata
Tickers: LLY, INCY
Executed On: Jun 17, 2022 at 02:45 PM EDT -
A Second View: Digging into Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo
Ticker: INCY
Executed On: Apr 05, 2022 at 01:00 PM EDT -
Digging into Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo
Ticker: INCY
Executed On: Apr 01, 2022 at 01:00 PM EDT -
Discussing the INCY's Opzelura Cream (Ruxolitinib) in treating atopic dermatitis with a prescriber
Ticker: INCY
Executed On: Mar 15, 2022 at 01:00 PM EDT
Expired Projects (INCY)
-
Examining the Market Potential for JAKs treating moderate-to-severe alopecia areata
Tickers: CNCE, LLY, PFE, INCY
Execute By: Jun 23, 2022 -
Discussing Incyte Corporation's Opzelura Cream (Ruxolitinib) in Atopic dermatitis, following recent FDA Approval
Ticker: INCY
Execute By: Oct 31, 2021
Upcoming & Overdue Catalysts (INCY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (INCY)
-
Incyte (INCY) Posts Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
Tickers: INCY, EQ
Occurred on: Jan 02, 2020 -
PDUFA date for Incyte's(INCY) Ruxolitinib in Graft versus host disease expected May 24, 2019
Ticker: INCY
Occurred on: May 24, 2019 -
Phase 1 poster presentation of Incyte's(INCY) INCMGA0012 in Solid tumors due at AACR April 1, 2019, 1pm.
Ticker: INCY
Occurred on: Apr 01, 2019 -
Incyte (INCY) phase 3 interim readout for Keytruda and epacadostat combo in advanced melanoma is expected in Q1, 2018. - Discontinued
Ticker: INCY
Occurred on: Apr 06, 2018 -
FDA Decision on Baricitinib Expected April 19 2017
Tickers: INCY, LLY
Occurred on: Apr 14, 2017 -
Incyte (INCY) Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi) in Graft-versus-Host Disease
Ticker: INCY
Occurred on: Dec 30, 2016 -
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD)
Ticker: INCY
Occurred on: Jun 23, 2016 -
Incyte set to initiate Phase 3 study of epacadostat plus pembrolizumab in first-line advanced melanoma
Tickers: INCY, MRK
Occurred on: Jun 22, 2016 -
Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study
Ticker: INCY
Occurred on: Jun 22, 2016 -
GITR and LSD1 programs to enter clinical trials in the first half of 2016.
Ticker: INCY
Occurred on: Jun 22, 2016 -
New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)
Ticker: INCY
Occurred on: Jun 10, 2016 -
Phase 3 data of Ruxolitinib - JANUS 1 trial for pancreatic, colorectal and breast cancer due 2016
Ticker: INCY
Occurred on: Feb 11, 2016 -
Incyte to Discontinue Phase 3 study (JANUS 1) of Ruxolitinib Plus Capecitabine
Ticker: INCY
Occurred on: Feb 11, 2016 -
NDA filing of Baricitinib for Rheumatoid arthritis to be filed by partner Eli Lilly in 2016
Ticker: INCY
Occurred on: Jan 19, 2016
Strategic Initiatives (INCY)
-
Incyte (INCY) and Agenus (AGEN) Announce Amended Collaboration Agreement
Tickers: AGEN, INCY
Announcement Date: Feb 14, 2017 -
Incyte (INCY) and Merck (MRK) Expand Collaboration Agreement Investigating Epacadostat + Keytruda in Solid Tumors and Blood Cancers
Tickers: MRK, INCY
Announcement Date: Jan 09, 2017 -
Incyte (INCY) and Merus N.V (MRUS) Reach Collaboration Agreement to Discover and Develop Bispecific Antibodies
Tickers: INCY, MRUS
Announcement Date: Dec 21, 2016 -
Incyte acquires the European operation of ARIAD Pharmaceuticals for $140M upfront plus milestones and tiered royalties
Tickers: INCY, ARIA
Announcement Date: May 09, 2016 -
AstraZeneca and Incyte announce new lung cancer clinical trial collaboration
Tickers: AZN, INCY
Announcement Date: Jan 11, 2016
